TrialJapanese journal of clinical oncology2017

Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study.

Seiichiro Ozono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.